Arthur J. Gallagher (AJG) Form 144 Filed for 12,855 Shares Worth $3.83M
Rhea-AI Filing Summary
Form 144 filed for Arthur J. Gallagher & Co. (AJG) shows a proposed sale of 12,855 common shares with an aggregate market value of $3,825,688.01, against 256,400,000 shares outstanding. The proposed sale date is 09/08/2025 on the NYSE through Fidelity Brokerage Services LLC.
The filing discloses the acquisition history for the shares to be sold: 4,100 shares from restricted stock vesting on 03/15/2025 (compensation), 1,155 shares from a deferred equity participation program on 04/01/2025 (compensation), and 7,600 shares from option exercise (option granted 03/14/2019) with payment in cash on 09/08/2025. The filer reports nothing to report for securities sold in the past three months and affirms no undisclosed material adverse information.
Positive
- Full compliance with Rule 144 disclosure requirements including acquisition dates and payment nature
- No prior sales in the past three months were reported, indicating this is not part of a rapid sell-down
Negative
- Proposed sale of 12,855 shares valued at $3,825,688.01 increases available supply from an insider
- Option exercise and cash sale on the same date (09/08/2025) could add shares to market liquidity that day
Insights
TL;DR: Routine insider sale notice for 12,855 AJG shares, largely from compensation vesting and an option exercise.
The Form 144 is a standard notification required when insiders or affiliated persons propose to sell restricted or control securities. The mix of vested restricted stock, deferred equity shares and option-related shares indicates planned liquidity events rather than an abrupt disposal. The aggregate value disclosed is $3.83 million, which represents a small fraction of the 256.4 million shares outstanding and is unlikely by itself to materially affect market supply.
TL;DR: Disclosure aligns with Rule 144 procedures; statements affirm lack of undisclosed material information.
The filing follows required disclosure format and includes the filer’s representation that no material adverse information is undisclosed. Acquisition dates and payment nature are clearly stated, including compensation origin and cash payment for option exercise. No prior three-month sales were reported, reducing concerns about rapid successive disposals by the filer.